Q&A: Long-term success of GLP-1 therapies hinges on more than just a prescription

GLP-1 (glucagon-like peptide-1) therapies can be powerful tools in managing obesity, with patients taking these medications seeing weight reductions of 5%–18% in clinical trials, along with increased metabolism and benefits to their overall heart health. However, GLP-1s can come with challenges, including gastrointestinal side effects, risk of micronutrient deficiencies, muscle and bone loss, poor long-term follow-through with weight regain if stopped, and high costs.

Leave A Comment

Your email address will not be published. Required fields are marked *